Jazz Pharmaceuticals(JAZZ) ZACKS·2025-03-14 14:45Core Insights - Zacks Premium provides tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future outlook through projected and historical earnings, sales, and cash flow [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns [9] Stock Highlight: Jazz Pharmaceuticals - Jazz Pharmaceuticals, based in Dublin, is a specialty biopharmaceutical company focusing on neuroscience and oncology, currently holding a Zacks Rank of 2 (Buy) and a VGM Score of A [11] - The company has a forward P/E ratio of 5.88, indicating strong value metrics, and has seen nine analysts revise earnings estimates higher for fiscal 2025, with the consensus estimate rising by 23.15 per share [12]